The days of Regeneron’s broad immuno-oncology collaboration with Sanofi are numbered.
The two companies agreed to wind down a partnership, launched in 2015, sooner than is strictly necessary, they announced Monday. Sanofi will pay out the rest of its committed investments plus termination fees — about $460 million.
About the Author Reprints
